Today: 19 May 2026
Browse Category

Biotechnology 6 February 2026 - 27 April 2026

Intellia Therapeutics Stock Jumps After Hours Ahead of First Phase 3 In Vivo CRISPR Readout

Intellia Therapeutics Stock Jumps After Hours Ahead of First Phase 3 In Vivo CRISPR Readout

Intellia Therapeutics will release Phase 3 data Monday from its HAELO trial of lonvoguran ziclumeran, an in vivo CRISPR gene-editing therapy for hereditary angioedema. The study enrolled 80 patients, testing a single 50 mg infusion against placebo. Intellia shares rose 19.3% after hours Friday ahead of the announcement. The company ended 2025 with $605.1 million in cash and expects it to last into late 2027.
25 April 2026
···
Eli Lilly to Buy Kelonia for Up to $7 Billion as In Vivo CAR-T Gains Ground

Eli Lilly to Buy Kelonia for Up to $7 Billion as In Vivo CAR-T Gains Ground

Eli Lilly will acquire Boston-based Kelonia Therapeutics for up to $7 billion in cash, including $3.25 billion upfront, to expand into in vivo CAR-T cancer therapies. Kelonia’s KLN-1010, in Phase 1 for multiple myeloma, generates engineered T-cells inside the patient. The deal marks Lilly’s third Massachusetts biotech purchase in 2026. Kelonia had 62 employees and nearly ran out of cash before the offer.
21 April 2026
··
Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
18 April 2026
··
Hims & Hers Stock Surges as FDA Reopens Peptide Rules, Shifting Focus Beyond GLP-1 Drama

Hims & Hers Stock Surges as FDA Reopens Peptide Rules, Shifting Focus Beyond GLP-1 Drama

Hims & Hers Health shares rose 14% to $24.29 after the FDA said it will review restrictions on several peptides, including BPC-157 and TB-500. The agency set a July advisory meeting and will remove some peptides from its safety-risk list within a week. Hims, which acquired a California peptide facility last year, reported $2.35 billion in 2025 revenue and 2.511 million subscribers.
15 April 2026
··
Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal

Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal

Soleno Therapeutics withdrew its European filing for VIOKAT on Tuesday, halting a regulatory review that was expected to conclude in 2026. The move came one day after Neurocrine Biosciences agreed to acquire Soleno for $2.9 billion in cash, or $53 a share. Vykat XR, Soleno’s only marketed product, generated $190.4 million in 2025 U.S. sales. Neurocrine said it has no immediate plans for a European launch.
7 April 2026
···
BioCryst (BCRX) stock price dips premarket as new navenibart HAE data lands; Cowen talk next

BioCryst (BCRX) stock price dips premarket as new navenibart HAE data lands; Cowen talk next

BioCryst Pharmaceuticals shares fell 2.9% to $8.50 premarket Monday after new clinical data on its hereditary angioedema drug pipeline. Interim results from the ALPHA-SOLAR study showed navenibart reduced mean monthly HAE attacks by 91% among 29 patients, with one discontinuation due to cancer. The company reaffirmed 2026 revenue guidance for ORLADEYO and expects a Phase 3 navenibart filing by late 2027.
2 March 2026
·
Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Eli Lilly shares rose 2.93% to $1,051.99 Friday, outperforming a falling market. Full results from a diabetes trial showed Lilly’s oral drug orforglipron caused more nausea and discontinuations than Novo Nordisk’s Rybelsus, but produced greater A1C and weight reduction. The 52-week study involved 1,698 patients. Novo plans to cut U.S. list prices for Ozempic and Wegovy by up to 50% starting in 2027.
28 February 2026
···
CRISPR Therapeutics stock whipsaws again as takeover talk resurfaces — here’s what to watch

CRISPR Therapeutics stock whipsaws again as takeover talk resurfaces — here’s what to watch

CRISPR Therapeutics shares fell 1.9% to $60.55 in premarket trading Friday after an 11.85% surge Thursday on renewed takeover speculation flagged by Betaville, The Fly reported. The company reported $116 million in 2025 Casgevy revenue and ended the year with $1.98 billion in cash. Management is set to appear at investor conferences starting March 2.
27 February 2026
···
Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK)

Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK)

Stoke Therapeutics shares dropped 1.2% to $35.80 in early premarket trading Tuesday, after a 5.7% gain the previous session. Wolfe Research began coverage with an “Outperform” rating and a $40 price target. Investors are watching for updates on the company’s Phase 3 Dravet syndrome trial with Biogen. About 21.6% of Stoke’s float is sold short, according to MarketBeat.
24 February 2026
···
Gossamer Bio stock tumbles again premarket as Phase 3 PAH miss rewrites the story

Gossamer Bio stock tumbles again premarket as Phase 3 PAH miss rewrites the story

Gossamer Bio shares traded near $0.42 in early premarket Tuesday after plunging about 80% when its main drug failed to meet the primary goal in a Phase 3 trial. The company said the study’s key endpoint improved by 13.3 meters but did not reach statistical significance. Analysts downgraded the stock and flagged risks around funding and regulatory timelines. Gossamer plans to meet the FDA and paused another study.
24 February 2026
···
Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly shares climbed nearly 5% late Monday after Novo Nordisk reported its obesity drug CagriSema underperformed Lilly’s Zepbound in a head-to-head trial. Novo’s U.S.-listed shares dropped over 16%. CagriSema showed 23% weight loss after 84 weeks, compared to 25.5% for Zepbound. The trial failed to prove CagriSema was not worse than tirzepatide on weight loss.
23 February 2026
····
GRAIL stock dives nearly 50% after UK Galleri trial misses key goal, raising FDA questions

GRAIL stock dives nearly 50% after UK Galleri trial misses key goal, raising FDA questions

GRAIL shares plunged nearly 50% to $51.00 after a UK trial showed its Galleri blood test missed the main goal of significantly improving early cancer detection. The study’s results complicate prospects for broad screening and reimbursement. Focus now shifts to U.S. regulators and Medicare-linked evidence. GRAIL reported Q4 revenue up 14% to $43.6 million and said its FDA approval submission is under review.
20 February 2026
··
Moderna stock price jumps late after earnings beat, but FDA flu setback hangs over MRNA

Moderna stock price jumps late after earnings beat, but FDA flu setback hangs over MRNA

Moderna shares climbed 5% to $42.23 in after-hours trading Friday after beating fourth-quarter revenue estimates and reaffirming its 2026 growth outlook. The FDA refused to file Moderna’s flu vaccine application, prompting the company to seek a Type A meeting. The flu shot is under review in Europe, Canada, and Australia. Moderna reported Q4 revenue of $678 million and a $2.11 per share loss.
13 February 2026
····
Roche share price set for Monday test after MS drug fenebrutinib data lands

Roche share price set for Monday test after MS drug fenebrutinib data lands

Roche said its experimental MS drug fenebrutinib met the main goal in a late-stage study for primary progressive multiple sclerosis, showing “non-inferiority” to Ocrevus but with more frequent, reversible liver enzyme elevations and a higher share of fatal cases. Roche shares last closed down 0.6% at 356.40 francs. Investors await Monday’s webcast for more data and filing plans.
8 February 2026
····
Eli Lilly stock rises after FDA steps up crackdown on GLP-1 copycats

Eli Lilly stock rises after FDA steps up crackdown on GLP-1 copycats

Eli Lilly shares climbed 3.7% in after-hours trading after the FDA announced plans to restrict GLP-1 ingredients in unapproved compounded drugs. Hims & Hers shares dropped nearly 12% after being referred for a Justice Department probe. Investors are watching for details on enforcement and pricing pressure as the market reacts to moves against copycat obesity drugs.
7 February 2026
···
Illumina (ILMN) stock slides 10% after 2026 outlook puts China, research demand back in focus

Illumina (ILMN) stock slides 10% after 2026 outlook puts China, research demand back in focus

Illumina shares dropped 10.3% to $119.91 after the company forecast 2026 revenue of $4.5–$4.6 billion and non-GAAP EPS of $5.05–$5.20. Management cited progress in China but said approvals are still needed for instrument sales. Fourth-quarter revenue rose 5% to $1.16 billion, with ex-China revenue up 8%. The company expects 2026 organic revenue growth of 2–4% excluding China.
6 February 2026
···
Thermo Fisher stock price today: TMO nudges higher after Thursday drop as investors eye next week’s data

Thermo Fisher stock price today: TMO nudges higher after Thursday drop as investors eye next week’s data

Thermo Fisher shares rose 0.6% to $545.58 Friday afternoon, recovering some ground after a 4% drop Thursday. The move lagged the broader market, with the S&P 500 up 1.73%. Investors remain cautious amid weak academic research funding and uncertain lab order trends. Upcoming U.S. jobs and inflation data could affect rate expectations and valuations.
6 February 2026
··
1 2 3 4 … 17

Stock Market Today

  • 5 TSX Dividend Stocks Yielding 3% to 5% for Reliable Cash Flow
    May 18, 2026, 10:18 PM EDT. Building a portfolio of TSX dividend stocks can deliver steady income and market resilience. Top picks include Enbridge (TSX:ENB), an energy infrastructure giant offering a 5.1% yield backed by decades of consistent dividend growth. RioCan REIT (TSX:REI.UN) provides a unique monthly dividend of 5.4%, combining commercial real estate and residential exposure in Canadian metros. Toronto-Dominion Bank (TSX:TD) stands out among big banks with a 2.9% yield, nearly two centuries of dividends, and strong U.S. growth. These selections cover varied sectors and offer investors dependable cash flow with defensive qualities amid market volatility.

Latest articles

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

19 May 2026
Dominion Energy shares jumped 9.4% after agreeing to an all-stock merger with NextEra Energy, whose shares fell 4.6%. The S&P 500 slipped 0.1% and the Nasdaq dropped 0.5% as investors sold technology stocks amid rising Treasury yields and oil prices. Nvidia fell 1.4% ahead of earnings. U.S. crude settled at $107.37, and the 10-year Treasury yield reached 4.59%.
XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

19 May 2026
XP Inc.’s U.S.-listed shares fell 3.78% in after-hours trading Monday after reporting higher Q1 profit but weaker net inflows and a lower retail take rate. Net income rose 7% to 1.32 billion reais, but net inflow dropped to 14 billion reais from 24 billion a year earlier. The company declared a $0.20 dividend and announced a new CFO, Gustavo Alejo Viviani, starting August 3.
LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

19 May 2026
Publicis Groupe agreed to buy LiveRamp Holdings for $38.50 a share in cash, valuing the U.S. data-collaboration firm at $2.546 billion. LiveRamp stock jumped to $37.77 on the news, while the broader market fell. LiveRamp reported fiscal Q4 revenue of $206 million, up 9% from a year earlier. Publicis said the deal will boost its adjusted earnings per share from the first year after closing.

Popular

Regeneron stock sinks after cancer trial miss prompts selloff

Regeneron stock sinks after cancer trial miss prompts selloff

19 May 2026
Regeneron Pharmaceuticals shares fell 9.8% to $629.68 Monday after its late-stage melanoma drug trial with fianlimab failed to meet the main goal. The study did not show a statistically significant benefit over Merck’s Keytruda. At least 10 brokerages cut price targets. The decline outpaced broader market losses, with the Nasdaq down 0.5%.
Go toTop